Q&A with Tareq Anani, co-founder and president
Nanoxort was formed in June 2018 as an Alabama limited liability company. Its mission is to provide safer diagnostic tools for patient populations that currently receive suboptimum care. Nanoxort currently has two full-time employees.
What does innovation mean to you?
To us, innovation means the advancement of science and engineering in ways that benefit the public in meaningful ways. As it pertains to the medical field, innovation must always take into account patient safety and wellbeing above all else.
What ways has your company innovated and/or created meaningful impact?
Nanoxort is developing nanotechnology-based solutions for biomedical imaging. Our products provide enhanced magnetic resonance imaging quality and are safer for patients with impaired kidney function, patients who need periodic MRI scans, pediatrics and patients who desire gadolinium-free products.
Our primary technology will provide an unmatched tool for vascular imaging, an area of medicine with a large clinical need and attractive market opportunity. The product has the potential to disrupt the current MRI contrast agent market because of its improved safety profile and higher imaging resolution of blood vessels compared to current gadolinium-based contrast agents. This creates a win-win-win scenario for everyone involved; for patients with vascular disease not only does it provide a safer alternative, but also a more accurate diagnosis that will allow doctors to prescribe safer, more effective treatments. For the patient’s family, it reduces financial and social burdens by enabling preventive treatment due to earlier disease detection. For radiologists, the clearer MRI images produced lead to more accurate diagnoses.
What else do you want people to know about your company?
At Nanoxort, one of our primary goals is to create opportunities for scientists who strive to innovate in nanotechnology, advance the MRI contrast market, and leave a positive impact on people's lives and the communities around them.
